Recent Articles

Found 71 Results
Page 1 of 8

Immuneering Appoints Biren Amin, M.B.A., as Chief Financial Officer

CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the appointment of Biren Amin, M.B.A., as Chief Financial Officer. Mr. Amin comes to Immuneering from Jefferies Financial…


Immuneering Expands Leadership Team with Appointment of Carolina Garcia Rizo, Ph.D., MBA, as Chief Business Officer

GLOBAL BUSINESS DEVELOPMENT LEADER JOINS EXECUTIVE TEAM TO CONTRIBUTE TO IMMUNEERING’S GROWTH CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation today announced Carolina Garcia Rizo, Ph.D., MBA, has…


Disease Cancelling Technology Emulates Sound Cancelling Technology to Mute Cancer

In this article by Gail Dutton, our co-founder and CEO Ben Zeskind discusses Immuneering’s proprietary Disease Cancelling Technology platform, and our growing pipeline of medicines targeting signaling pathways that are…


Disease-cancelling drugs: Immuneering raises $62m in Series B round

In this article by Allie Nawrat, our co-founder and CEO Ben Zeskind discusses Immuneering’s recent financing of $62m, in an oversubscribed Series B round led by high-profile life science investors….


Immuneering secures $62M series B to advance tech-driven pipeline

In this article by Michael Fitzhugh, Immuneering co-founder and CEO Ben Zeskind discusses the company’s recent oversubscribed Series B financing, which raised a total of $62M to advance its Disease…


Immuneering Completes Oversubscribed $62 Million Series B Financing

Financing to support advancement of Immuneering’s lead drug programs targeting cancers driven by alterations in the RAS/MAPK pathway and pipeline development of earlier programs in neuroscience and immuno-oncology.


Biomarkers Show the Power of Contexualization

In this Genetic Engineering & Biotechnology News article by Richard A. Stein, Immuneering’s Head of Neuroscience J.L. Ross, Ph.D. discusses the company’s integration of biomarkers with bioinformatic, proteomic, and gene signature information…


Silencing gene expression to cure complex diseases

In this article by Zach Winn, Immuneering co-founder and CEO Ben Zeskind discusses his journey from MIT undergraduate to biotech entrepreneur. He speaks to the company’s decade-plus of experience helping…


Immuneering to Present at Oppenheimer’s Private Life Sciences Company Call Series

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020. Immuneering…


Immuneering Enters Collaboration with Astex Pharmaceuticals to Identify Novel Therapeutic Targets in Central Nervous System Disorder Using Disease Cancelling Technology

CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a wholly owned subsidiary…


Page 1 of 8